- Home
- BNR vs NRXP Comparison
BNR vs NRXP Comparison
Compare BNR & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- NRXP
- Stock Information
- Founded
- BNR 2014
- NRXP 2015
- Country
- BNR China
- NRXP United States
- Employees
- BNR N/A
- NRXP N/A
- Industry
- BNR Medical Specialities
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- BNR Health Care
- NRXP Health Care
- Exchange
- BNR Nasdaq
- NRXP Nasdaq
- Market Cap
- BNR 30.9M
- NRXP 34.7M
- IPO Year
- BNR 2020
- NRXP N/A
- Fundamental
- Price
- BNR $2.94
- NRXP $1.98
- Analyst Decision
- BNR
- NRXP Strong Buy
- Analyst Count
- BNR 0
- NRXP 4
- Target Price
- BNR N/A
- NRXP $28.25
- AVG Volume (30 Days)
- BNR 20.3K
- NRXP 128.2K
- Earning Date
- BNR 05-28-2025
- NRXP 05-13-2025
- Dividend Yield
- BNR N/A
- NRXP N/A
- EPS Growth
- BNR N/A
- NRXP N/A
- EPS
- BNR N/A
- NRXP N/A
- Revenue
- BNR $70,669,261.00
- NRXP N/A
- Revenue This Year
- BNR $136.32
- NRXP N/A
- Revenue Next Year
- BNR N/A
- NRXP N/A
- P/E Ratio
- BNR N/A
- NRXP N/A
- Revenue Growth
- BNR N/A
- NRXP N/A
- 52 Week Low
- BNR $2.62
- NRXP $1.10
- 52 Week High
- BNR $8.99
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- BNR 24.38
- NRXP 48.76
- Support Level
- BNR $2.77
- NRXP $1.85
- Resistance Level
- BNR $3.29
- NRXP $1.97
- Average True Range (ATR)
- BNR 0.30
- NRXP 0.16
- MACD
- BNR 0.01
- NRXP 0.03
- Stochastic Oscillator
- BNR 13.82
- NRXP 71.43
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.